1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Tianda Pharmaceuticals Limited

Tianda Pharmaceuticals Limited

0455.HK
Tianda Pharmaceuticals LimitedHK flagHong Kong Stock Exchange
0.09
HKD
+0.00
- -
195.65MMarket Cap
Tianda Pharmaceuticals Limited
0455.HK
(Hong Kong Stock Exchange)

Recent

price

0.09

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2022
2023
2024
2025
FRC
0.07
0.05
0.1
0.13
0.07
0.09
0.09
0.17
0.25
0.23
0.22
0.24
- -
0.25
0.15
- -
Revenue per Share
0.04
0.02
0.02
0.01
-0.01
- -
0.01
- -
- -
- -
-0.01
-0.01
- -
-0.01
-0.03
- -
Basic EPS, GAAP
0.03
0.03
0.06
0.02
-0.03
- -
0.02
0.02
-0.01
-0.06
-0.08
-0.03
- -
-0.05
-0.02
- -
Free Cash Flow per Basic Share
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.22
0.19
0.22
0.22
0.21
0.21
0.2
0.2
0.2
0.2
0.18
0.1
- -
0.13
0.1
- -
Book Value per Share
0.46
0.46
0.3
0.33
0.32
0.33
0.31
0.29
0.3
0.29
0.31
0.31
- -
0.22
0.16
- -
Tangible Book Value per Share
1,555
1,870
1,870
1,870
1,870
2,050
2,151
2,151
2,150
2,150
2,150
2,150
- -
2,150
2,150
- -
Basic Weighted Avg Shares
104
97
180
247
139
193
196
362
527
491
474
510
- -
532
330
323
Sales/Revenue/Turnover
57.02
53.01
30.99
24.98
-23.18
4.81
9.9
4.53
2.4
2
-6.58
-8.24
- -
-4.59
-15.17
-15.96
Operating Margin (%)
11
24
19
18
19
21
25
22
16
20
21
22
- -
36
38
39
Depreciation Expense
67
43
38
22
-18
7
12
10
3
3
-27
-20
- -
-24
-61
-70
Net Income, GAAP
15.54
25.24
19.25
24.02
- -
27.45
24.42
25.98
38.92
44.75
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
65.05
44.3
20.94
8.92
-12.87
3.41
6.36
2.77
0.5
0.64
-5.72
-3.88
- -
-4.54
-18.6
-21.67
Profit Margin (%)
587
404
394
432
391
411
417
482
542
449
392
306
196
31
-35
-41
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
20
122
99
71
11
3
46
LT Debt
847
870
775
815
788
847
813
886
811
760
790
789
654
592
506
456
Total Equity
7.56
4.41
5.41
5.82
- -
0.82
1.75
1.41
0.9
0.67
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
10.1
1.27
1.63
-1.05
- -
-0.05
0.03
-0.46
-2.3
-0.49
- -
- -
- -
- -
- -
- -
Return on Capital (%)
30.73
12.44
10.03
5.36
-4.43
1.6
2.89
2.32
0.62
0.74
-6.6
-6.47
- -
-9.64
-24.04
-36.93
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-5.69%
-10.22%
-9.75%
Free Cash Flow
- -
- -
-87.42%
Net Income, GAAP
- -
- -
14.06%
Sales/Revenue/Turnover
- -
- -
-2.12%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
532
2024
- -
- -
- -
- -
330
2025
- -
- -
- -
- -
323

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.01
2024
- -
- -
- -
- -
-0.03
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
AusCann Group Holdings Ltd (ACNNF)
GelStat Corporation (GSAC)
Gridiron BioNutrients, Inc. (GMVP)
Laurus Labs Limited (LAURUSLABS.BO)
Stemcell United Limited (SCU.AX)
Sunset Island Group, Inc. (SIGO)
Business
Tianda Pharmaceuticals Limited (0455.HK) is an investment holding company engaged in the research, development, manufacture and sale of pharmaceutical, biotechnology and healthcare products primarily in Mainland China, Hong Kong and Australia. Founded in 1992 and headquartered in Central, Hong Kong, the company operates through three main segments including Pharmaceuticals and Medical Technologies, Chinese Medicine, and Medical and Healthcare Services; it offers a comprehensive product portfolio encompassing Chinese medicines such as ZhiKang Granules, chemical drugs including Tuoping Valsartan Capsules and Ai Sen Ao Aceglutamide for Injection, biological products like Zhentai Cerebroprotein Hydrolysate Injection and Gan Fu Xin Vinpocetine Injection, health products under the self-owned Herb Valley and Tuokang brands featuring Pu’er Tea Cream series and throat lozenges, medical appliances, as well as CDMO/CMO services and traditional Chinese medicine decoction pieces; therapeutic areas cover cardio-cerebrovascular, paediatric, anti-flu and respiratory, anti-infection, detoxification, anti-cancer and others, with distribution through nationwide marketing networks, retailers and subsidiaries in key regions. A subsidiary of Tianda Group Limited, the company maintains R&D centres and production bases in Zhuhai and Kunming that hold GMP certifications from Chinese and Australian authorities, alongside marketing centres in Shenzhen and Sydney. Recent developments include the launch of four new products in 2024 covering respiratory, hypertension and paediatric asthma areas such as Ibuprofen Suspension, Nicorandil for Injection and Metformin Hydrochloride and Empagliflozin Tablets; completion of two CDE registration applications and advancement of three ongoing projects alongside re-registration of two core products, bringing CDMO/CMO offerings to 12 products; operational startup of Tianda Chinese Medicine (Bozhou) Ltd in late 2024 to bolster the TCM supply chain with authentic medicinal materials like earthworm and safflower; opening of the Jordan TDMall clinic in Hong Kong in October 2024 as an oncology treatment centre under the TDMall brand; positive Phase II clinical trial results for Baoxin Granules in treating chronic heart failure with preparation for Phase III; board changes in 2025 appointing Mr. Zhu Haomiao as non-executive director, Mr. Lam Yat Fai as lead independent non-executive director and Dr. Xian Yanfang to the nomination committee; and strategic deepening of client cooperation while expanding e-commerce, OTC and third-terminal channels amid national procurement adaptations.